Page last updated: 2024-11-04

risedronic acid and Airflow Obstruction, Chronic

risedronic acid has been researched along with Airflow Obstruction, Chronic in 2 studies

Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Research Excerpts

ExcerptRelevanceReference
"High lung deposition and bioavailability of RIS was monitored with 88."1.72Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF-κB and RhoA/ROCK1/MLCP signaling. ( Cao, J; Chen, H; Chen, R; Liu, D; Su, B; Tang, Y; Wu, D; Xu, J; Xu, W, 2022)
"We analyzed patients with chronic obstructive pulmonary disease whose bone mineral density were measured at least three times over three years (n = 111)."1.51Predictive and modifying factors of bone mineral density decline in patients with COPD. ( Asano, K; Betsuyaku, T; Chubachi, S; Fukunaga, K; Irie, H; Kameyama, N; Nakamura, H; Sakurai, K; Sasaki, M; Sayama, K; Tsutsumi, A, 2019)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Liu, D1
Xu, W1
Tang, Y1
Cao, J1
Chen, R1
Wu, D1
Chen, H1
Su, B1
Xu, J1
Kameyama, N1
Chubachi, S1
Sasaki, M1
Tsutsumi, A1
Irie, H1
Sakurai, K1
Sayama, K1
Nakamura, H1
Asano, K1
Betsuyaku, T1
Fukunaga, K1

Other Studies

2 other studies available for risedronic acid and Airflow Obstruction, Chronic

ArticleYear
Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF-κB and RhoA/ROCK1/MLCP signaling.
    Respiratory research, 2022, Dec-28, Volume: 23, Issue:1

    Topics: Airway Obstruction; Animals; Inflammation; Lung; Mice; NF-kappa B; Prenylation; Pulmonary Disease, C

2022
Predictive and modifying factors of bone mineral density decline in patients with COPD.
    Respiratory medicine, 2019, Volume: 148

    Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Comorbidity; Female; Humans

2019